此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Silevertinib联合替莫唑胺治疗新诊断的未甲基化MGMT和EGFRvIII胶质母细胞瘤研究

2026年11月9日 更新者:Black Diamond Therapeutics, Inc.

一项2期随机、多中心研究,旨在评估口服EGFR抑制剂Silevertinib联合替莫唑胺在未甲基化MGMT启动子和EGFRvIII新诊断胶质母细胞瘤患者中的疗效和安全性

The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting.

Specifically, this study is being done to find answers to the following questions:

  • How much of the study drugs (silevertinib combined with temozolomide) should be given to participants with GBM?
  • What are the side effects participants have when taking the study drug (silevertinib combined with temozolomide)?
  • Can the study drug (silevertinib combined with temozolomide) help participants with GBM live longer without disease progression compared to treatment with temozolomide alone?

研究概览

详细说明

Silevertinib was designed to block a growth signal important to some cancers where tumors grow because of changes in a protein called epidermal growth factor receptor (EGFR). These changes are called gene amplifications, mutations, or alterations and are found in tumors. Temozolomide is a drug that fights cancer cells by damaging DNA (the genetic material of cells), which could cause the tumor cells to die. It is the standard treatment for adults with certain types of newly diagnosed brain cancer, like GBM. It is given together with radiotherapy and sometimes afterward as maintenance therapy.

This study has 2 parts. To be eligible for the study, participants must have received a diagnosis of GBM, had surgery to remove or reduce the size of the tumor, and received adjuvant radiation therapy and temozolomide. No other prior treatments for GBM are allowed.

In Part 1 (called the Safety Lead-in), participants will receive silevertinib combined with temozolomide to determine if the combination is safe and to find the best dose. Approximately 12 participants are expected to enroll in Part 1 of the study.

In Part 2, all participants will be randomized to one of two different treatment groups:

  • Group 1: Silevertinib + temozolomide
  • Group 2: Temozolomide only

Approximately 150 participants are expected to be randomized in Part 2 of the study.

In both Part 1 and Part 2, the study treatment will be given in "cycles". Each cycle will be 28 days. After a cycle ends, the next cycle will immediately begin the next day. Both silevertinib and temozolomide will be taken orally. Silevertinib is taken daily until disease progression and temozolomide is taken for the first 5 days of each cycle (up to 6 cycles).

If participants are found to be eligible for the study and enrolled (in Part 1) or randomized (in Part 2), participants will:

  • Take the study drug as directed
  • Return for frequent clinic visits to monitor overall health and status of GBM
  • Undergo imaging and other laboratory tests to determine status of GBM
  • Complete a paper diary at home to record the date and time(s) that the study drug is taken

研究类型

介入性

注册 (估计的)

162

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Alabama
      • Birmingham、Alabama、美国、35233
        • 招聘中
        • University of Alabama at Birmingham O'Neal Comprehensive Cancer Center
        • 接触:
    • Arkansas
      • Springdale、Arkansas、美国、72762
        • 招聘中
        • Highlands Oncology Group
        • 接触:
    • California
      • La Jolla、California、美国、92037-0845
        • 招聘中
        • UCSD Moores Cancer Center
        • 接触:
      • Los Angeles、California、美国、90048
        • 招聘中
        • Cedars-Sinai Medical Center
        • 接触:
      • Orange、California、美国、92868
        • 招聘中
        • UC Irvine Health
        • 接触:
      • Palo Alto、California、美国、94304
    • Connecticut
      • New Haven、Connecticut、美国、06510
        • 招聘中
        • Yale Cancer Center
        • 接触:
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20016
        • 招聘中
        • Johns Hopkins Sibley Memorial Hospital
        • 接触:
    • Florida
      • Miami、Florida、美国、33176
      • Tampa、Florida、美国、33612
        • 招聘中
        • Moffitt Cancer Center
        • 接触:
    • Georgia
      • Atlanta、Georgia、美国、30318
    • Maine
      • Scarborough、Maine、美国、04074
        • 招聘中
        • Maine Health Cancer Care and Blood Disorders - Scarborough
        • 接触:
    • Maryland
      • Baltimore、Maryland、美国、21287
        • 招聘中
        • Johns Hopkins Sidney Kimmel Cancer Center - Baltimore
        • 接触:
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • 招聘中
        • Massachusetts General Hospital
        • 接触:
      • Boston、Massachusetts、美国、02215
        • 招聘中
        • Beth Israel Deaconess Medical Center
        • 接触:
      • Boston、Massachusetts、美国、02215
    • Michigan
      • Ann Arbor、Michigan、美国、48109
      • Detroit、Michigan、美国、48202
        • 招聘中
        • Henry Ford Cancer- Detroit
        • 接触:
        • 接触:
    • Minnesota
      • Minneapolis、Minnesota、美国、55455
    • Missouri
      • St Louis、Missouri、美国、63108
        • 招聘中
        • Washington University School of Medicine Siteman Cancer Center
        • 接触:
    • Nebraska
      • Omaha、Nebraska、美国、68106
        • 招聘中
        • University of Nebraska Medical Center
        • 接触:
    • New Jersey
      • Hackensack、New Jersey、美国、07601
        • 招聘中
        • John Theurer Cancer Center at Hackensack University Medical Center
        • 接触:
      • New Brunswick、New Jersey、美国、08901
        • 招聘中
        • Rutgers Cancer Institute
        • 接触:
      • Summit、New Jersey、美国、07901
    • New York
      • Lake Success、New York、美国、11042
        • 招聘中
        • Northwell Health Center for Advanced Medicine - Brain Tumor Center
        • 接触:
      • New York、New York、美国、10032
      • The Bronx、New York、美国、10461
        • 招聘中
        • Montefiore Medical Center
        • 接触:
    • North Carolina
      • Charlotte、North Carolina、美国、28204
      • Winston-Salem、North Carolina、美国、27157
    • Ohio
      • Cleveland、Ohio、美国、44195
        • 招聘中
        • Cleveland Clinic Taussig Cancer Center
        • 接触:
      • Columbus、Ohio、美国、43210
        • 招聘中
        • Ohio State University
        • 接触:
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107
        • 招聘中
        • Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center
        • 接触:
      • Pittsburgh、Pennsylvania、美国、15232
        • 招聘中
        • UPMC Hillman Cancer Center
        • 接触:
    • South Carolina
      • Greenville、South Carolina、美国、29605
    • Texas
      • Houston、Texas、美国、77030
        • 招聘中
        • UT MD Anderson Cancer Center
        • 接触:
    • Utah
      • Salt Lake City、Utah、美国、84112
        • 招聘中
        • Huntsman Cancer Institute, University of Utah
        • 接触:
    • Virginia
      • Fairfax、Virginia、美国、22031
      • Richmond、Virginia、美国、23298
        • 招聘中
        • VCU Massey Comprehensive Cancer Center
        • 接触:
    • Wisconsin
      • Madison、Wisconsin、美国、53792
        • 招聘中
        • University of Wisconsin Carbone Cancer Center
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • Newly diagnosed histologically confirmed glioblastoma that is isocitrate dehydrogenase wild type (IDH-WT).
  • Positive EGFR status in the brain tumor as determined by a commercially available test or validated laboratory assay (CLIA or comparable certification).
  • For Part 1 (Safety Lead-in) ONLY: EGFR alterations.
  • For Part 2 (Randomized, Controlled Trial) ONLY: EGFRvIII.
  • For Part 2 (Randomized, Controlled Trial) ONLY: Unmethylated MGMT promoter tumor status based on a validated assay.
  • No treatment for newly diagnosed GBM other than surgery followed by standard-of-care adjuvant postoperative radiation (54 to 60 Gy) and TMZ chemotherapy.
  • At least 4 weeks since completion of radiation therapy, with a post-radiation MRI showing no progression.

Key Exclusion Criteria:

  • Recurrent multifocal disease, metastatic, leptomeningeal, or extracranial GBM, or gliomatosis cerebri.
  • Progression of GBM prior to Enrollment, Screening, or Randomization.
  • Biopsy-only/no resectional surgery.
  • Prior or concomitant treatment for GBM with an EGFR-targeting agent, including silevertinib, bevacizumab, cytotoxic chemotherapy, immunotherapy, experimental therapies, Gliadel wafers, GammaTile®, or other intratumoral or intracavitary antineoplastic therapy.
  • Intent to use Optune® (TTF).
  • Significant other uncontrolled health conditions or other malignancies.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:silevertinib and temozolomide

silevertinib at dose determined in Part 1 until disease progression in combination with temozolomide 150-200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle for maximum of 6 cycles

Participants enrolled into Part 1 (Safety Lead-In) or randomized to Arm A in Part 2 will receive silevertinib at dose determined in Part 1 until disease progression in combination with temozolomide 150-200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle for maximum of 6 cycles.

其他名称:
  • 特莫达尔
  • TMZ
  • BDTX-1535
有源比较器:temozolomide

temozolomide 150-200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle for maximum of 6 cycles

Participants randomized to Arm B will receive temozolomide 150-200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle for maximum of 6 cycles

其他名称:
  • 特莫达尔
  • TMZ

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR)
大体时间:12 months

Progression-free survival, defined as the time from the date of randomization to the date of first disease progression per RANO 2.0 by BICR assessment or death from any cause, whichever occurs first.

12 months

次要结果测量

结果测量
措施说明
大体时间
Overall Survival
大体时间:18 months

Overall survival defined as time from first dose of study drug to death from any cause.

18 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月5日

初级完成 (估计的)

2028年11月1日

研究完成 (估计的)

2029年3月1日

研究注册日期

首次提交

2026年1月7日

首先提交符合 QC 标准的

2026年1月7日

首次发布 (实际的)

2026年1月8日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年5月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅